Claims for Patent: 10,053,504

Summary for Patent: 10,053,504

Title:	SPARC binding ScFvs
Abstract:	The invention provides compositions comprising SPARC binding ScFv and its use.
Inventor(s):	Trieu; Vuong (Agoura Hills, CA)
Assignee:	ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:	15/132,647
Patent Claims:	1. A method for treating cancer differentially expressing SPARC in a mammalian subject comprising: (a) preparing a composition comprising one or more SPARC binding ScFvs whose amino acid sequences consist of SEQ ID NOS: 113-116, wherein each of the one or more ScFvs specifically binds SPARC and is conjugated to: i) a cytotoxic moiety that is effective to inhibit the proliferation and/or survival of cancer cells in the mammalian subject, or ii) an antibody fragment comprising a functional antibody Fc domain capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC), and wherein the composition, optionally, further comprises a pharmaceutically acceptable carrier; and (b) administering to a mammalian subject a therapeutically effective amount of the composition. 2. The method of claim 1, wherein the functional antibody Fc domain comprises SEQ ID NO: 118. 3. The method of claim 1, wherein the cytotoxic moiety is selected from the group consisting of a radionuclide, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, melphalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosourea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, combretastatins, discodermolides, transplatinum, 5-fluorouracil, genistein, Truncated Tissue Factor ("tTF"), Tumor Necrosis Factor ("TNF"), Scaffold Matrix Attachment Region binding protein 1 ("Smar1") derived p44 peptide, interferon, TNF-Related Apoptosis-Inducing Ligand ("TRAIL"), Second-Mitochondria Activator of Caspases ("Smac"), Von Hipel-Lindau tumor suppressor ("VHL") procaspase, caspase, IL-2, a non-Fc domain antibody fragment, and combinations thereof. 4. The method of claim 1, wherein the mammalian subject is a human.

Details for Patent 10,053,504

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-12-05
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-12-05
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2028-12-05